Grant: Idea to Innovation
University of Calgary
$20,000.00
L2M NSERC - Novel Materials for Skin Harvest
FY 2023-24
Summary
Dermatome is mainly used in skin graft for applications include 1) chronic burn care treatment, 2) general surgery, 3) plastic surgery, and 4) reconstruction surgeries. According to Market Research Report, the skin graft market in North America is expected to grow from US$ 426.44 million in 2021 to US$ 664.40 million by 2028; it is estimated to grow at a CAGR of 6.5% from 2021 to 2028 [1]. The Center for Disease Control (CDC) stated that more than 1.1 million people suffer burn injuries that need medical care every year in the US. According to the Healthcare Cost and Utilization Project, in US, over 160,000 skin grafts are performed annually for burn hospitalizations [2]. Undermanagement for the tears at the donor sites will leave to chronic wounds and profound cost to public health system. Donor site dressings were estimated at A$67 (uncomplicated) to A$175 (complicated/delayed healing) per patient [3]. If burn-related skin grafts in Canada account for 10% of that in US, each patient receives graft from one donor site, and average donor site dressing costs USD$150, annual SAM in US and Canada for burn hospitalization patients would be USD$26 million. Other indications which have rising need for skin graft procedures include diabetic ulcer and skin cancer. The rising prevalence of diabetic foot ulcers has been significantly impacting the demand for dermatome devices. 15% of diabetic patients will have foot ulcer[4], and 1 in 5 of those will be hospitalized for the condition. If 20% hospitalized diabetic patients will receive skin graft, the annual SAM for skin graft in diabetic foot ulcer patients in US and Canada will be $30 million. At its current stage, we have successfully designed and printed the modified dermatome, marking a significant milestone in the project. Our focus has now shifted to optimizing the hydrogel dressing through experimentation with different biomaterial concentrations. This optimization process includes a comprehensive characterization approach evaluating crucial parameters such as gelation time, rheology, swelling, water loss, tensile strength, degradation, gel fraction, SEM (scanning electron microscopy), adhesion, biocompatibility, and hemostasis effect. This multifaceted characterization effort ensures a thorough understanding of the hydrogel's performance and properties, laying the groundwork for its efficacy in clinical applications. Furthermore, we are actively working on assessing the hydrogel's performance on donor site wounds, with potential trials on horse wounds in the near future. While currently in the optimization and characterization phase, this innovative solution holds promising potential to address critical challenges in donor-site wound care.
Program
Idea to Innovation
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
590711-2024
Name nom
Gabriel, Vincent A
Department département
Cumming School of Medicine
Organization id
11
Institution établissement
University of Calgary
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2024
Award amount
20000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
9032
Research subject group en
Aucune de ces Catégories
Research subject group fr
Medical sciences
Research subject en
Not Classified
Research subject fr
Sciences médicales
Application title
L2M NSERC - Novel Materials for Skin Harvest
Keyword
biomedical engineering; hydrogel; medical devices; surgery; wound healing
Application summary
Dermatome is mainly used in skin graft for applications include 1) chronic burn care treatment, 2) general surgery, 3) plastic surgery, and 4) reconstruction surgeries. According to Market Research Report, the skin graft market in North America is expected to grow from US$ 426.44 million in 2021 to US$ 664.40 million by 2028; it is estimated to grow at a CAGR of 6.5% from 2021 to 2028 [1]. The Center for Disease Control (CDC) stated that more than 1.1 million people suffer burn injuries that need medical care every year in the US. According to the Healthcare Cost and Utilization Project, in US, over 160,000 skin grafts are performed annually for burn hospitalizations [2]. Undermanagement for the tears at the donor sites will leave to chronic wounds and profound cost to public health system. Donor site dressings were estimated at A$67 (uncomplicated) to A$175 (complicated/delayed healing) per patient [3]. If burn-related skin grafts in Canada account for 10% of that in US, each patient receives graft from one donor site, and average donor site dressing costs USD$150, annual SAM in US and Canada for burn hospitalization patients would be USD$26 million. Other indications which have rising need for skin graft procedures include diabetic ulcer and skin cancer. The rising prevalence of diabetic foot ulcers has been significantly impacting the demand for dermatome devices. 15% of diabetic patients will have foot ulcer[4], and 1 in 5 of those will be hospitalized for the condition. If 20% hospitalized diabetic patients will receive skin graft, the annual SAM for skin graft in diabetic foot ulcer patients in US and Canada will be $30 million. At its current stage, we have successfully designed and printed the modified dermatome, marking a significant milestone in the project. Our focus has now shifted to optimizing the hydrogel dressing through experimentation with different biomaterial concentrations. This optimization process includes a comprehensive characterization approach evaluating crucial parameters such as gelation time, rheology, swelling, water loss, tensile strength, degradation, gel fraction, SEM (scanning electron microscopy), adhesion, biocompatibility, and hemostasis effect. This multifaceted characterization effort ensures a thorough understanding of the hydrogel's performance and properties, laying the groundwork for its efficacy in clinical applications. Furthermore, we are actively working on assessing the hydrogel's performance on donor site wounds, with potential trials on horse wounds in the near future. While currently in the optimization and characterization phase, this innovative solution holds promising potential to address critical challenges in donor-site wound care.